Download PDF

Nature Metabolism

Publication date: 2022-06-01
Pages: 693 -
Publisher: Nature Research

Author:

Kay, Emily J
Paterson, Karla ; Riero-Domingo, Carla ; Sumpton, David ; Dabritz, J Henry M ; Tardito, Saverio ; Boldrini, Claudia ; Hernandez-Fernaud, Juan R ; Athineos, Dimitris ; Dhayade, Sandeep ; Stepanova, Ekaterina ; Gjerga, Enio ; Neilson, Lisa J ; Lilla, Sergio ; Hedley, Ann ; Koulouras, Grigorios ; McGregor, Grace ; Jamieson, Craig ; Johnson, Radia Marie ; Park, Morag ; Kirschner, Kristina ; Miller, Crispin ; Kamphorst, Jurre J ; Loayza-Puch, Fabricio ; Saez-Rodriguez, Julio ; Mazzone, Massimiliano ; Blyth, Karen ; Zagnoni, Michele ; Zanivan, Sara

Keywords:

Science & Technology, Life Sciences & Biomedicine, Endocrinology & Metabolism, TGF-BETA, PYRUVATE-DEHYDROGENASE, BREAST-CARCINOMA, TUMOR-GROWTH, LUNG-CANCER, COLLAGEN-VI, METABOLISM, EXPRESSION, DRIVES, PROGRESSION, Breast Neoplasms, Cancer-Associated Fibroblasts, Carcinogenesis, Collagen, Extracellular Matrix, Female, Glutamine, Humans, Proline, Pyrroline Carboxylate Reductases, delta-1-Pyrroline-5-Carboxylate Reductase, Immunofit - 773208;info:eu-repo/grantAgreement/EC/H2020/773208, 3205 Medical biochemistry and metabolomics, 3208 Medical physiology, 3210 Nutrition and dietetics

Abstract:

Elevated production of collagen-rich extracellular matrix is a hallmark of cancer-associated fibroblasts (CAFs) and a central driver of cancer aggressiveness. Here we find that proline, a highly abundant amino acid in collagen proteins, is newly synthesized from glutamine in CAFs to make tumour collagen in breast cancer xenografts. PYCR1 is a key enzyme for proline synthesis and highly expressed in the stroma of breast cancer patients and in CAFs. Reducing PYCR1 levels in CAFs is sufficient to reduce tumour collagen production, tumour growth and metastatic spread in vivo and cancer cell proliferation in vitro. Both collagen and glutamine-derived proline synthesis in CAFs are epigenetically upregulated by increased pyruvate dehydrogenase-derived acetyl-CoA levels. PYCR1 is a cancer cell vulnerability and potential target for therapy; therefore, our work provides evidence that targeting PYCR1 may have the additional benefit of halting the production of a pro-tumorigenic extracellular matrix. Our work unveils new roles for CAF metabolism to support pro-tumorigenic collagen production.